Company intelligence
Persist AI
10x faster formulation development with on-premise AI
Pharmaceutical Manufacturing
West Sacramento, US
11–50 employees
Founded 2022
3 public signals
About Persist AI
Developing drug formulations takes years of trial and error. We enable Pharma and CDMOs to shorten formulation discovery time by utilizing our AI models in their cloud. Our AI models are built and validated on high throughput data from our robotic lab in Sacramento, CA.
Verified activity
Signals from Persist AI
3 published signals
Capital & Finance
Persist AI was informed that Samsung Biologics announced a $1.8 billion tender for PolyPeptide Group.
Reported by Karthik Raman, PhD
Research & Knowledge
Persist AI learned that Celltrion's Omlyclo is the first interchangeable biosimilar that replaces Xolair in the clinic.
Reported by Karthik Raman, PhD
Legal & Regulatory
Persist AI noted that Xspray received its fourth Complete Response Letter from the FDA regarding the drug Dasynoc, which is an amorphous solid dispersion reformulation of dasatinib.
Reported by Karthik Raman, PhD